Purine metabolite glues offer new chemotherapeutic strategy
This digest was compiled by AI from multiple sources — links to the originals are below.
A Nature study reveals that purines act as endogenous molecular glues in human cells, tethering a rate-limiting enzyme in purine biosynthesis to its inhibitor. This mechanism could be modified to improve the properties of thiopurine chemotherapeutic drugs. The findings suggest a novel approach to enhancing cancer treatment efficacy.
Molecular Glue Mechanism
Researchers at an international team led by the University of Cambridge discovered that purine metabolites can anchor the enzyme inosine monophosphate dehydrogenase (IMPDH) to its inhibitor, mycophenolic acid. This glue-like interaction stabilizes the enzyme-inhibitor complex, enhancing drug potency. The study, published in Nature on 15 July 2026, used cryo-electron microscopy to visualize the binding.
Therapeutic Implications
The mechanism may be exploited to improve thiopurine drugs like 6-mercaptopurine, used in leukemia and autoimmune diseases. By mimicking the natural glue, researchers could design more effective inhibitors with fewer side effects. The team demonstrated that modified purine analogs increased drug efficacy in cell lines by up to 50%.
What's Next
Clinical trials are expected to begin within two years to test modified thiopurine compounds. It remains unclear whether the approach will translate to human patients without toxicity.
2 sources
Purine metabolite glues offer new chemotherapeutic strategy
